ERN EURO-NMD expert opinion on management of new biologic therapies in myasthenia gravis

Myasthenia Gravis is a potentially life-threatening autoimmune disease of the neuromuscular junction with fluctuating muscle weakness and fatigability. In recent years, the therapeutic landscape has been notably reshaped by the introduction of new therapies. These agents, primarily acting through complement inhibition or neonatal Fc-receptor blockade, have demonstrated significant efficacy and favorable safety profiles in randomized clinical trials and real-world settings. Their advent has refined clinical management, particularly in refractory patients, leading to meaningful improvements in patients' quality of life and future expectations. Meanwhile, in this evolving therapeutic landscape, new challenges and uncertainties in clinical decision-making have been raised, as new therapies are now part of the standard care in Myasthenia Gravis. Differences in regulatory agency approvals and reimbursement policies across Europe result in heterogeneous access to therapies, complicating treatment decisions and limiting shared real-world experiences. Consequently, clinicians face complex dilemmas regarding optimal patient selection, treatment choice, and long-term management strategies. To address these issues, a panel of experts, including adult and pediatric neurologists and patient representatives, within the framework of the European Reference Network for Neuromuscular Diseases convened to develop consensus-based positions. The aim of this work was to identify, explore, and discuss key challenges associated with the use of new therapies and to propose a practical approach to support clinicians in this rapidly evolving field. Given the variability in clinical approach, treatment availability and reimbursement policies across European healthcare systems, this position paper seeks to provide guidance that are adaptable across diverse settings. A literature review was conducted, focusing on pivotal clinical trials and real-world evidence. Eleven key topics were identified and discussed, and for each, consensus statements were developed and refined through a modified Delphi process: patient assessment from both clinician and patient perspectives; the role of autoantibodies and optimization of serological testing; selection of immunotherapies; definitions of treatment response and failure in the context of new therapies; strategies for switching between therapies; predictors of treatment response; management of concomitant therapies, including corticosteroids and conventional immunosuppressant; discontinuation strategies; their potential role as early-line therapies; their applicability in ocular MG; and future therapeutic perspectives, including ongoing clinical trials. In conclusion, new therapies represent a major advance in Myasthenia Gravis care but also introduce significant complexity. This expert position paper provides a framework to support clinicians in decision-making and highlights the need for harmonized guidelines and further research to optimize their use in routine practice.

Authors

Institutions

Publication Details

Journal
Brain
Published
2026-11-19
DOI
https://doi.org/10.1093/brain/awag407
Primary Topic
Myasthenia Gravis and Thymoma
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ERN EURO-NMD expert opinion on management of new biologic therapies in myasthenia gravis

Elena Cortés‐Vicente, John Vissing, Marta Cheli, Nils Erik Gilhus et al.
Brain
Myasthenia Gravis and Thymoma
article

ERN EURO-NMD expert opinion on management of new biologic therapies in myasthenia gravis

Elena Cortés‐Vicente, John Vissing, Marta Cheli, Nils Erik Gilhus, Sithara Ramdas, Anthony Béhin, Anna Rostedt Punga, Andreas Meisel, Lorenzo Maggi, Anna Kostera‐Pruszczyk, Maria Bonaria Uccheddu, Voháňka Stanislav, Allard Lutgarde
article en

Abstract

Myasthenia Gravis is a potentially life-threatening autoimmune disease of the neuromuscular junction with fluctuating muscle weakness and fatigability. In recent years, the therapeutic landscape has been notably reshaped by the introduction of new therapies. These agents, primarily acting through complement inhibition or neonatal Fc-receptor blockade, have demonstrated significant efficacy and favorable safety profiles in randomized clinical trials and real-world settings. Their advent has refined clinical management, particularly in refractory patients, leading to meaningful improvements in patients' quality of life and future expectations. Meanwhile, in this evolving therapeutic landscape, new challenges and uncertainties in clinical decision-making have been raised, as new therapies are now part of the standard care in Myasthenia Gravis. Differences in regulatory agency approvals and reimbursement policies across Europe result in heterogeneous access to therapies, complicating treatment decisions and limiting shared real-world experiences. Consequently, clinicians face complex dilemmas regarding optimal patient selection, treatment choice, and long-term management strategies. To address these issues, a panel of experts, including adult and pediatric neurologists and patient representatives, within the framework of the European Reference Network for Neuromuscular Diseases convened to develop consensus-based positions. The aim of this work was to identify, explore, and discuss key challenges associated with the use of new therapies and to propose a practical approach to support clinicians in this rapidly evolving field. Given the variability in clinical approach, treatment availability and reimbursement policies across European healthcare systems, this position paper seeks to provide guidance that are adaptable across diverse settings. A literature review was conducted, focusing on pivotal clinical trials and real-world evidence. Eleven key topics were identified and discussed, and for each, consensus statements were developed and refined through a modified Delphi process: patient assessment from both clinician and patient perspectives; the role of autoantibodies and optimization of serological testing; selection of immunotherapies; definitions of treatment response and failure in the context of new therapies; strategies for switching between therapies; predictors of treatment response; management of concomitant therapies, including corticosteroids and conventional immunosuppressant; discontinuation strategies; their potential role as early-line therapies; their applicability in ocular MG; and future therapeutic perspectives, including ongoing clinical trials. In conclusion, new therapies represent a major advance in Myasthenia Gravis care but also introduce significant complexity. This expert position paper provides a framework to support clinicians in decision-making and highlights the need for harmonized guidelines and further research to optimize their use in routine practice.

Brain
University of Copenhagen (DK), Uppsala University Hospital (SE), Medical University of Warsaw (PL), Haukeland University Hospital (NO), Hospital de Sant Pau (ES), Rigshospitalet (DK), John Radcliffe Hospital (GB), Humboldt-Universität zu Berlin (DE), University of Oxford (GB), Assistance Publique – Hôpitaux de Paris (FR), University Hospital Brno (CZ), Institut de Myologie (FR), Pitié-Salpêtrière Hospital (FR), Fondazione IRCCS Istituto Neurologico Carlo Besta (IT), Stiftung Charité (DE), University of Bergen (NO), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE)
Myasthenia Gravis and Thymoma
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon